These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12402931)

  • 1. EC approves irbesartan for the treatment of diabetic renal disease.
    Cardiovasc J S Afr; 2002; 13(4):216-7. PubMed ID: 12402931
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prospective treatment study of irbesartan. Diabetic kidneys regain function].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145(41):41. PubMed ID: 14655481
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
    Palmer AJ; Roze S; Rodby RA; Valentine WJ; Ritz E; Lehnert H
    Dtsch Med Wochenschr; 2006 Aug; 131(31-32):1721-6. PubMed ID: 16868875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
    Palmer AJ; Valentine WJ; Ray JA
    Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II receptor blockers and nephropathy trials.
    Bloomgarden ZT
    Diabetes Care; 2001 Oct; 24(10):1834-8. PubMed ID: 11574450
    [No Abstract]   [Full Text] [Related]  

  • 6. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Ritz E
    Dtsch Med Wochenschr; 2004 Jan; 129(1-2):13-8. PubMed ID: 14703575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
    MMW Fortschr Med; 2001 Aug; 143(31-32):44. PubMed ID: 11556191
    [No Abstract]   [Full Text] [Related]  

  • 8. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
    Frei A; Palmer AJ; Burnier M; Hess B
    Praxis (Bern 1994); 2006 Mar; 95(11):401-8. PubMed ID: 16570646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the impact of PRIME on real-life diabetic nephropathy?
    Ruilope LM
    Int J Clin Pract; 2004 Mar; 58(3):268-76. PubMed ID: 15117095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.
    Ann Intern Med; 2003 Apr; 138(7):I43. PubMed ID: 12667050
    [No Abstract]   [Full Text] [Related]  

  • 12. Irbesartan slows the development of diabetic nephropathy by up to 70% in hypertensive diabetic patients.
    Cardiovasc J S Afr; 2001; 12(4):242-3. PubMed ID: 11766619
    [No Abstract]   [Full Text] [Related]  

  • 13. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria: response to Andersen, Brochner-Mortensen, and Parving.
    Kaiser T; Florack C; Sawicki PT
    Diabetes Care; 2004 Jun; 27(6):1521; author reply 1521-2. PubMed ID: 15161820
    [No Abstract]   [Full Text] [Related]  

  • 14. [Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress].
    de Alvaro F
    Nefrologia; 2001; 21 Suppl 3():76-82. PubMed ID: 11642211
    [No Abstract]   [Full Text] [Related]  

  • 15. Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure.
    Cardiovasc J S Afr; 2001; 12(4):240-1. PubMed ID: 11766617
    [No Abstract]   [Full Text] [Related]  

  • 16. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
    Bold KO
    MMW Fortschr Med; 2001 May; 143(22):12-3. PubMed ID: 11460392
    [No Abstract]   [Full Text] [Related]  

  • 18. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
    Palmer AJ; Roze S; Valentine WJ; Ray JA; Frei A; Burnier M; Hess B; Spinas GA; Brändle M
    Swiss Med Wkly; 2006 May; 136(21-22):346-52. PubMed ID: 16779715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
    Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
    Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Health economic aspects of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
    Schute LL
    Dtsch Med Wochenschr; 2004 Jun; 129(25-26):1448; author reply 1448. PubMed ID: 15213879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.